APAC Zika Virus Vaccines Market

APAC Zika Virus Vaccines Market Size (2024 to 2029)

The Zika Virus Vaccines Market size in the Asia Pacific was worth USD 2.99 billion in 2024 and estimated to be growing at a CAGR of 7.56% to reach USD 4.34 billion by 2029.

Zika virus is a mosquito-borne fever caused by Aedes mosquitoes when they are active in the day-time. It is similar to yellow fever, West Nile virus, and dengue. Zika vaccines are developed to prevent and control diseases caused by zika virus. This disease has no symptoms or sometimes very mild symptoms like a minimal form of dengue fever, skin rash, and joint pains. It is transmitted sexually from the infected person or the infected pregnant woman to the baby.

There are different types of vaccines developing to protect against viruses, such as mRNA vaccines, DNA-based vaccines, genetically engineered vaccines, and inactivated vaccines. With the rise in zika virus incidences, many pharmaceutical and biotechnology companies are investing in this market. In very rare cases, the zika virus is also transmitted through blood transfusion. In 2016, the World Health Organization (WHO) declared that the major causes of the zika virus were asymptomatic.

Factors like rising incidences of zika virus, growing people awareness about zika infection, high investment by private companies in the R&D of zika virus, serious attention due to high risk to the pregnant women, favorable government reimbursements, potential demand for zika vaccine, and technology advancements in the healthcare industry are driving the Asia-Pacific Zika Virus Vaccines market.

However, the lack of awareness among the people and WHO announcing it as an epidemic projected to have less potential in the coming days is hindering the market growth.

This research report on the APAC Zika Virus Vaccines Market has been segmented & sub-segmented into the following categories:

By Type:

• Therapeutic Vaccines
• Preventive Vaccines

By End-User:

• Hospitals
• Clinics
• Research Institutes
• Others

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, Asia-Pacific is anticipated to have the fastest-growing rate with the highest CAGR during the forecast period. This is due to the presence of emerging economies like India and China, which attracted strong pharmaceutical companies.

Notable companies operating in the APAC Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline plc., Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.